<html><head><link rel="stylesheet" type="text/css" href="usc.css"/><title>U.S.C. Title 21 - FOOD AND DRUGS</title></head><body>
<span style="font-weight:bold;font-size:12pt;">21 U.S.C. </span><br/>
<span style="font-size:10pt">United States Code, 2011 Edition</span><br/>
<span style="font-size:10pt">Title 21 - FOOD AND DRUGS</span><br/>
<span style="font-size:10pt">CHAPTER 9 - FEDERAL FOOD, DRUG, AND COSMETIC ACT</span><br/>
<span style="font-size:10pt">SUBCHAPTER VII - GENERAL AUTHORITY</span><br/>
<span style="font-size:10pt">Part C - Fees</span><br/>
<span style="font-size:10pt">subpart 2 - fees relating to drugs</span><br/>
<span style="font-size:10pt">Sec. 379h-2 - Reauthorization; reporting requirements</span><br/>
<span style="font-size:10pt">From the U.S. Government Printing Office, <a href="http://www.gpo.gov">www.gpo.gov</a></span><br/><br/>
<!-- documentid:21_379h-2  usckey:210000000037900000000000h00020000 currentthrough:20120103 documentPDFPage:346 -->
<!-- itempath:/210/CHAPTER 9/SUBCHAPTER VII/Part C/subpart 2/Sec. 379h-2 -->
<!-- itemsortkey:210AAKN -->
<!-- expcite:TITLE 21-FOOD AND DRUGS!@!CHAPTER 9-FEDERAL FOOD, DRUG, AND COSMETIC ACT!@!SUBCHAPTER VII-GENERAL AUTHORITY!@!Part C-Fees!@!subpart 2-fees relating to drugs!@!Sec. 379h-2 -->
<!-- field-start:head -->
<h3 class="section-head">&sect;379h&ndash;2. Reauthorization; reporting requirements</h3>
<!-- field-end:head -->
<!-- field-start:statute -->
<h4 class="subsection-head">(a) Performance report</h4>
<p class="statutory-body">Beginning with fiscal year 2008, not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 101(c) of the Food and Drug Administration Amendments Act of 2007 during such fiscal year and the future plans of the Food and Drug Administration for meeting the goals. The report for a fiscal year shall include information on all previous cohorts for which the Secretary has not given a complete response on all human drug applications and supplements in the cohort.</p>
<h4 class="subsection-head">(b) Fiscal report</h4>
<p class="statutory-body">Beginning with fiscal year 2008, not later than 120 days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year.</p>
<h4 class="subsection-head">(c) Public availability</h4>
<p class="statutory-body">The Secretary shall make the reports required under subsections (a) and (b) available to the public on the Internet Web site of the Food and Drug Administration.</p>
<h4 class="subsection-head">(d) Reauthorization</h4>
<h4 class="paragraph-head">(1) Consultation</h4>
<p class="statutory-body-1em">In developing recommendations to present to the Congress with respect to the goals, and plans for meeting the goals, for the process for the review of human drug applications for the first 5 fiscal years after fiscal year 2012, and for the reauthorization of this subpart for such fiscal years, the Secretary shall consult with&mdash;</p>
<p class="statutory-body-2em">(A) the Committee on Energy and Commerce of the House of Representatives;</p>
<p class="statutory-body-2em">(B) the Committee on Health, Education, Labor, and Pensions of the Senate;</p>
<p class="statutory-body-2em">(C) scientific and academic experts;</p>
<p class="statutory-body-2em">(D) health care professionals;</p>
<p class="statutory-body-2em">(E) representatives of patient and consumer advocacy groups; and</p>
<p class="statutory-body-2em">(F) the regulated industry.</p>
<h4 class="paragraph-head">(2) Prior public input</h4>
<p class="statutory-body-1em">Prior to beginning negotiations with the regulated industry on the reauthorization of this subpart, the Secretary shall&mdash;</p>
<p class="statutory-body-2em">(A) publish a notice in the Federal Register requesting public input on the reauthorization;</p>
<p class="statutory-body-2em">(B) hold a public meeting at which the public may present its views on the reauthorization, including specific suggestions for changes to the goals referred to in subsection (a);</p>
<p class="statutory-body-2em">(C) provide a period of 30 days after the public meeting to obtain written comments from the public suggesting changes to this subpart; and</p>
<p class="statutory-body-2em">(D) publish the comments on the Food and Drug Administration's Internet Web site.</p>
<h4 class="paragraph-head">(3) Periodic consultation</h4>
<p class="statutory-body-1em">Not less frequently than once every month during negotiations with the regulated industry, the Secretary shall hold discussions with representatives of patient and consumer advocacy groups to continue discussions of their views on the reauthorization and their suggestions for changes to this subpart as expressed under paragraph (2).</p>
<!-- PDFPage:347 --><h4 class="paragraph-head">(4) Public review of recommendations</h4>
<p class="statutory-body-1em">After negotiations with the regulated industry, the Secretary shall&mdash;</p>
<p class="statutory-body-2em">(A) present the recommendations developed under paragraph (1) to the Congressional committees specified in such paragraph;</p>
<p class="statutory-body-2em">(B) publish such recommendations in the Federal Register;</p>
<p class="statutory-body-2em">(C) provide for a period of 30 days for the public to provide written comments on such recommendations;</p>
<p class="statutory-body-2em">(D) hold a meeting at which the public may present its views on such recommendations; and</p>
<p class="statutory-body-2em">(E) after consideration of such public views and comments, revise such recommendations as necessary.</p>
<h4 class="paragraph-head">(5) Transmittal of recommendations</h4>
<p class="statutory-body-1em">Not later than January 15, 2012, the Secretary shall transmit to the Congress the revised recommendations under paragraph (4), a summary of the views and comments received under such paragraph, and any changes made to the recommendations in response to such views and comments.</p>
<h4 class="paragraph-head">(6) Minutes of negotiation meetings</h4>
<h4 class="subparagraph-head">(A) Public availability</h4>
<p class="statutory-body-2em">Before presenting the recommendations developed under paragraphs (1) through (5) to the Congress, the Secretary shall make publicly available, on the public Web site of the Food and Drug Administration, minutes of all negotiation meetings conducted under this subsection between the Food and Drug Administration and the regulated industry.</p>
<h4 class="subparagraph-head">(B) Content</h4>
<p class="statutory-body-2em">The minutes described under subparagraph (A) shall summarize any substantive proposal made by any party to the negotiations as well as significant controversies or differences of opinion during the negotiations and their resolution.</p>
<!-- field-end:statute -->
<!-- field-start:sourcecredit -->
<p class="source-credit">(June 25, 1938, ch. 675, &sect;736B, as added Pub. L. 110&ndash;85, title I, &sect;105, Sept. 27, 2007, 121 Stat. 840.)</p>
<!-- field-end:sourcecredit -->
<!-- field-start:notes -->
<!-- field-start:futureamendment-note -->
<h4 class="futureamend-note-head">Termination of Section</h4>
<p class="futureamend-note-body">For termination of section by section 106(b) of Pub. L. 110&ndash;85, see Effective and Termination Dates note below.</p>
<!-- field-end:futureamendment-note -->
<!-- field-start:referenceintext-note -->
<h4 class="note-head">References in Text</h4>
<p class="note-body">Section 101(c) of the Food and Drug Administration Amendments Act of 2007, referred to in subsec. (a), is section 101(c) of Pub. L. 110&ndash;85, which is set out as a note under section 379g of this title.</p>
<!-- field-end:referenceintext-note -->
<!-- field-start:effectivedate-terminationdate-note -->
<h4 class="note-head">Effective and Termination Dates</h4>
<p class="note-body">Pub. L. 110&ndash;85, title I, &sect;106(b), Sept. 27, 2007, 121 Stat. 842, provided that: &ldquo;The amendment made by section 105 [enacting this section] ceases to be effective January 31, 2013.&rdquo;</p>
<p class="note-body">Section effective Oct. 1, 2007, with fees under this subpart to be assessed for all human drug applications received on or after Oct. 1, 2007, see section 107 of Pub. L. 110&ndash;85, set out as an Effective and Termination Dates of 2007 Amendment note under section 379g of this title.</p>
<!-- field-end:effectivedate-terminationdate-note -->
<!-- field-end:notes -->


</body></html>